Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ceritinib in ALK-positive NSCLC with brain and/or leptomeningeal metastases
2014-000578-20Phase 2Completed
- Sponsor
- Novartis
- Start
- Feb 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of ceritinib in non-small cell lung cancer (NSCLC), Carcinomatous Meningitis (CM) and brain metastases (5 cohorts), sponsored by Novartis. Primary endpoint: Overall response rate. Started Feb 2015; status: completed.
02
Drugs
ceritinib
03
Conditions
non-small cell lung cancer (NSCLC)Carcinomatous Meningitis (CM)brain metastases
Beyond the preview
Go deeper on 2014-000578-20.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-000578-20.